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Abstract 
Clinical guidelines in the US and UK recommend that individuals with suspected 
hypertension should have ambulatory blood pressure (BP) monitoring (ABPM) to confirm 
the diagnosis. This approach reduces misdiagnosis due to white coat hypertension but will 
not identify people with masked hypertension who may benefit from treatment. The 
Predicting Out-of-Office Blood Pressure (PROOF-BP) algorithm predicts masked and white 
coat hypertension based on patient characteristics and clinic BP, improving the accuracy of 
diagnosis whilst limiting subsequent ABPM. This study assessed the cost-effectiveness of 
using this tool in diagnosing hypertension in Primary Care. A Markov cost-utility cohort 
model was developed to compare diagnostic strategies: the PROOF-BP approach, including 
those with clinic BP ≥130/80mmHg who receive ABPM as guided by the algorithm, 
compared to current standard diagnostic strategies including those with clinic BP 
≥140/90mmHg combined with further monitoring (ABPM as reference, clinic and home 
monitoring also assessed). The model adopted a lifetime horizon with a three month time-
cycle, taking a UK Health Service/Personal Social Services perspective. The PROOF-BP 
algorithm was cost-effective in screening all patients with clinic BP ≥130/80mmHg 
compared to current strategies which only screen those with clinic BP ≥140/90mmHg, 
provided healthcare providers were willing to pay up to £20,000 ($26,000)/quality-adjusted 
life year gained. Deterministic and probabilistic sensitivity analyses supported the base-case 
findings. The PROOF-BP algorithm appears to be cost-effective compared to the 
conventional BP diagnostic options in Primary Care. Its use in clinical practice is likely to lead 
to reduced cardiovascular disease, death and disability. 
Key words: raised blood pressure; general practice; cohort simulation; cost utility analysis  
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Introduction 
Hypertension is one of the most important modifiable risk factors for cardiovascular 
morbidity and mortality.1 Accurate measurement of blood pressure (BP) is essential to 
ensure that treatment is targeted appropriately. In the UK, the National Institute for Health 
and Care Excellence (NICE) published new guidelines on the diagnosis of hypertension in 
Primary Care in 2011.2 These recommended that all individuals with high BP readings in the 
clinic should be referred for ambulatory BP monitoring (ABPM) to confirm a diagnosis of 
hypertension, before initiating treatment. This recommendation was based on a systematic 
review of the clinical evidence and a Markov model-based cost-utility analysis comparing 
three different BP monitoring methods (clinic [CBPM], self-monitoring at home [HBPM] and 
ABPM) for making a diagnosis of hypertension in individuals with a screening clinic BP 
measurement equal-to-or-above 140/90 mm Hg.3,4 ABPM was found to be the most cost-
effective option across all age and gender subgroups. Despite ABPM being more expensive 
in terms of diagnostic costs, better targeting of treatment meant that it saved money in the 
long term by treating fewer individuals with white coat hypertension. Similar arguments 
have since been used in North America and Japan where out-of-office measurement is now 
also recommended.5,6 
White coat hypertension is the term used to describe when an individual has raised clinic BP 
(≥140/90 mm Hg) but is normotensive on ABPM (≤135/85 mm Hg).7 Individuals with white 
coat hypertension are at lower cardiovascular disease risk compared to individuals with 
sustained hypertension.8 Conversely, individuals with normotensive clinic BP measurements 
(<140/90 mm Hg) but hypertensive ambulatory BP measurements (>135/85 mm Hg) are 
referred to as having masked hypertension and have an increased risk of cardiovascular 
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events which approaches that of overt hypertension.9,10 Individuals with potential masked 
hypertension were not included in the population assessed in the health economics analysis 
that informed the NICE guideline2 as their screening clinic BP measurement would have 
been less than 140/90 mm Hg. 
The Predicting Out-of-Office Blood Pressure (PROOF-BP) algorithm calculates a predicted 
home clinic BP difference based on an individuals’ characteristics (age, sex, body mass 
index, past diagnosis of hypertension, cardiovascular disease, and antihypertensive 
prescription) and clinic BP, to guide utilisation of ABPM (Table S1 in the online-only Data 
Supplement). Adding this predicted difference to the known clinic BP of an individual 
provides the ‘adjusted clinic BP’ which has been shown to be closer to the true out-of-office 
blood pressure.11 Used as a triaging tool for ABPM (Figure 1), it has been shown to improve 
the accuracy of hypertension diagnosis (masked hypertension, sustained hypertension and 
white coat hypertension) without appreciably increasing use of ABPM.11 This study aimed to 
assess the cost-effectiveness of a strategy of targeted use of ABPM using the PROOF-BP 
algorithm in the diagnosis of hypertension in a primary care setting using an adaptation of 
the cost-effectiveness model used to inform the 2011 NICE guideline.  
 
Methods 
Full methods of the original health economic assessment that informed the NICE guideline 
have been described elsewhere.3,4 The original model assessed the cost-effectiveness of 
each BP monitoring method (CBPM, HBPM & ABPM) for confirming a diagnosis in people 
with suspected hypertension (clinic BP ≥140/90 mm Hg). This model, developed in Microsoft 
Excel, was modified by comparing the original diagnostic strategies with use of the PROOF-
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BP algorithm as a comparator. The base case model entry population was expanded to men 
and women aged 40 to 75 years with a screening clinic BP of ≥130/80 mm Hg although the 
management of those with clinic BP between 130-139/80-89 mm Hg was only affected in 
the PROOF-BP arm (see below). Model inputs were also updated where appropriate. 
Study population 
Data for the screening patient population, defined according to their clinic BP (Table S3 in 
the online-only Data Supplement), were taken from the Health Survey for England12 and 
adjusted clinic BPs were calculated using the PROOF-BP risk algorithm.11  
Model comparators 
The new model compared four methods of BP monitoring in the diagnosis of hypertension. 
Those approaches examined in the original model – CBPM [monthly measurements over 3 
months], HBPM [measurements over a week] and ABPM [measurements over 24 hours] – 
were compared to the new PROOF-BP diagnostic strategy (Figure 1): 
– The CBPM, HBPM, or ABPM diagnostic strategies were unchanged from the original 
model: 
– Individuals were not considered for diagnosis or treatment if their 
screening clinic BP was less than 140/90 mm Hg.  
– For those with a screening clinic BP of 140/90 mm Hg or over, they 
either underwent further clinic measurement, home monitoring or 
ABPM, exactly as in the original model. 
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– The PROOF BP strategy operated for all with a screening clinic BP of 130/80 mm Hg 
or over (i.e. everyone). They had an adjusted BP calculated using the PROOF BP 
algorithm and then proceeded as follows: 
– If the individual had an adjusted clinic BP < 130/80 mm Hg, no further 
action was required and they were measured again at the next check-
up period. 
– If the individual had an adjusted clinic BP between 130/80-144/89 
mm Hg, they received ABPM for confirmatory diagnosis. 
– If the individual had an adjusted clinic BP ≥145/90 mm Hg, true 
hypertensive status was assumed and treatment was offered without 
confirmatory ABPM diagnosis. 
Model structure 
A simplified Markov model diagram of the health states and the movements between states 
allowed to occur in a cycle is shown in Figure 2. In keeping with the original model, a model 
cycle length of three months was chosen as that approximated the average length of time 
for a complete CBPM diagnosis.2 HBPM, ABPM and the PROOF-BP algorithm were assumed 
to take one month for a complete diagnosis. In the suspected and diagnosed stages of the 
model, individuals could suffer a fatal or non-fatal cardiovascular event (stable angina, 
unstable angina, stroke, myocardial infarction [MI], and transient ischemic attack [TIA]). As 
per the original model, after suffering a non-fatal cardiovascular event, repeat clinical 
events were not modelled and individuals remained in a post-cardiovascular event state 
until they died. 
6 
 
PROOF-BP Economic Evaluation 
In the model, normotensive individuals could become hypertensive over time and those 
with an initial screening clinic BP of <140/90 mm Hg could move to >140/90 mm Hg. For 
model simplification purposes, it was assumed individuals could not become hypertensive 
while being assessed in the diagnostic pathway. Individuals not diagnosed with 
hypertension were assumed to have a BP check-up with CBPM at least every 5 years. In 
common with the original model, a failure rate was incorporated into ABPM. If ABPM failed 
(any cause of failure from a technical or a patient’s view), individuals were assumed to be 
put on HBPM. In the PROOF-BP algorithm strategy, if individuals had a screening clinic BP of 
less than 140/90 mm Hg and ABPM failed, it was assumed they remained undiagnosed (as in 
the HBPM strategy where these individuals were not considered for hypertension diagnosis) 
and their BP was rechecked every five years. This was due to a lack of data on the sensitivity 
and specificity of HBPM for those with a clinic BP of less than 140/90 mm Hg. 
Clinical model parameters are detailed in Table 1. Correct diagnosis of hypertension 
depended on the sensitivity and specificity of the test strategy used. As in the original 
model, test characteristics for CBPM and HBPM were taken from a meta-analysis13 with 
ABPM assumed to be the reference standard (100% sensitivity & 100% specificity). The test 
characteristics of the PROOF-BP algorithm with respect to their clinic BP and adjusted clinic 
BP categories are shown in Table S2 in the online-only Data Supplement.  
Model outcomes 
Risk of coronary heart disease and stroke were calculated using the Framingham risk 
equations14 by combining age, sex, and BP with the general population prevalence of risk 
factors in the Health Survey for England.12 Individuals with masked hypertension were 
assumed to have the same higher risk of cardiovascular events as sustained hypertensives.15 
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A hypertension diagnosis resulted in prescription of antihypertensive drug therapy and true 
hypertensive individuals received benefit in terms of cardiovascular risk reduction from such 
treatment. True normotensive individuals were assumed to receive no risk reduction from 
treatment (this assumption is relaxed in a sensitivity analysis). The proportion of individuals 
on different antihypertensive drug classes was based on treatment guidelines.2  
Quality of life and cost data are shown in Table 2. Baseline gender and age specific quality of 
life (utility) weights were taken from the Health Survey for England16 and applied to the 
cohorts. In the base case, individuals were assumed not to suffer any quality of life 
reductions (disutility) as a result of antihypertensive treatment.  
Model costs 
A more detailed description of costs is given in the extended methods in the online 
appendix. Costs were updated where necessary to 2013-2014 prices using the Hospital & 
Community Health Services (HCHS) index.17 Resource usage by diagnostic method and 
device usage assumptions were in line with the original model.4  
Analysis 
Results were presented as the total costs and effects of each diagnostic strategy (ordered by 
increasing cost). Effectiveness was measured in quality-adjusted life years (QALYs). 
Incremental Cost-Effectiveness Ratios (ICERs) were calculated from the difference in costs 
and effects between two options. Cost-effectiveness was assessed in relation to the NICE 
lower threshold of £20,000 per QALY.18 More costly and less effective (dominated) options 
were excluded from consideration. The analysis adopted a lifetime horizon and all costs and 
outcomes were discounted at the standard 3·5% rate.19 Costs and outcomes were 
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considered from a UK National Health Service (NHS)/Personal Social Services (PSS) 
perspective.  
Sensitivity analyses 
Uncertainty was explored via sensitivity analyses. Additional model runs were undertaken to 
determine the impact of changing key parameters on the model results. The following 
univariate sensitivity analysis was undertaken on all cohorts: model entry criteria were 
varied up and down, expanded to a screening clinic BP ≥120/70 mm Hg population (Table S4 
in the online-only Data Supplement) and then restricted to a screening clinic BP ≥140/90 
mm Hg population (Table S5 in the online-only Data Supplement). In line with the original 
model, sensitivity analyses were performed using the males aged 60 years subgroup. The 
following scenarios were explored: 
(i) A treatment disutility of 1% was assumed. This was equivalent to a quarter of the 
individuals suffering a quality of life reduction of 4% and everyone else suffering 
no ill effects of treatment. 
(ii) A treatment disutility of 2% was assumed. This was equivalent to a quarter of the 
individuals suffering a quality of life reduction of 8% and everyone else suffering 
no ill effects of treatment; 
(iii) Antihypertensive treatment risk reduction was based on half doses of 
medication; 
(iv) Antihypertensive drug costs were increased by 30%; 
(v) ABPM (reference) strategy to confirm diagnosis was undertaken in all patients 
with a screening clinic BP of ≥130/80 mm Hg; 
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(vi) The BP check-up frequency for those not diagnosed with hypertension was 
reduced from every five years to every three years; 
(vii) The prevalence of masked hypertension was increased and decreased by 25% 
respectively; 
(viii) Antihypertensive treatment risk reduction for masked hypertension was based 
on half doses;  
(ix) Antihypertensive treatment risk reduction for all treated people (i.e. those who 
are not truly hypertensive also gain benefit from BP reduction); 
(x) Antihypertensive treatment risk reduction assumed to be same as intensive 
treatment from the SPRINT trial.20 
(xi) The failure rate of ABPM was increased from 5% to 17%21 
Where available, data were inputted into the model as distributions in order to fully 
incorporate the uncertainty around parameter values for a probabilistic sensitivity analysis 
(PSA). The PSA ran for 1000 iterations across all cohorts for the three different model 
entries respectively. The number of times a strategy was the most cost-effective diagnostic 
option for each simulation (i.e. produced the highest net benefit) was expressed as a 
percentage for all cohorts. Positive count data from the PROOF-BP risk algorithm test 
characteristics formed the parameters for a Dirichlet distribution.  
 
Results 
In the base-case analysis (Table 3), the use of the PROOF-BP algorithm to triage for ABPM 
was cost-effective in all age and gender cohorts compared to the current NICE standard 
ABPM strategy and dominated the other comparators (saved costs and increased QALYs). 
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This was because of the influence of treating otherwise unrecognised cases of masked 
hypertension (see Table S6 in the online-only Data Supplement for number of initial 
misdiagnosis by strategy). For example, in a cohort of 1000 males aged 60, with a screening 
BP of 130/80 mm Hg or above, using the PROOF-BP algorithm would result in 62 more true 
hypertension cases detected, 5 more CVD events prevented (excluding fatal CHD & CVD 
deaths), 19.6 QALYs gained and increased total costs by £32,929 compared to standard 
ABPM (£1,680 per QALY gained). A detailed breakdown of costs and events for all age 
cohorts can be seen in Tables S7-S8. Using the PROOF-BP algorithm, with a screening BP of 
130/80 mm Hg or above, reduced the number of ABPM investigations in all age cohorts 
except for 40 year old (male & female) and 50 year old females compared with the NICE 
standard ABPM strategy (Table S9 in the online-only Data Supplement). 
The PROOF-BP algorithm was also cost-effective when the model entry was widened to 
individuals with a screening BP ≥120/70 mm Hg (Table S10 in the online-only Data 
Supplement). The PSA results indicated that for the base-case and ≥120/70 mm Hg model 
populations, PROOF-BP was the most cost-effective option in all iterations. When entry to 
the model was restricted to individuals with a screening BP ≥140/90 mm Hg (Table S11 in 
the online-only Data Supplement), PROOF-BP was the most cost-effective option except in 
the 40 year female old cohort. Univariate sensitivity analysis (Table 4) demonstrated that 
the model was sensitive to the assumption of quality of life reduction from treatment. For 
example, if a quarter of the individuals suffered a quality of life reduction of 8% and 
everyone else suffered no ill effects of treatment, PROOF-BP was dominated (more costly, 
less health gain) by the standard ABPM strategy. Use of the PROOF-BP algorithm was also 
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cost-effective compared to a strategy of utilising ABPM in all individuals with a screening BP 
of >130/80 mm Hg, which was cheaper, but resulted in fewer QALYs gained. 
 
Discussion 
This represents the first economic evaluation to compare the cost-effectiveness of using the 
PROOF-BP algorithm with strategies to diagnose hypertension which includes the 
consideration of individuals with potential masked hypertension. Targeted use of ABPM 
using the PROOF-BP algorithm was the most cost-effective diagnostic option for individuals 
presenting with a screening clinic BP of 130/80 mm Hg or above. The increased quality of 
life arising from use of the PROOF-BP algorithm was mainly due to identification and 
treatment of masked hypertension (and the subsequent CVD events avoided) which was 
ignored by the other strategies. The results were robust to several sensitivity analyses 
examining treatment disutility caused by side-effects to medication, adjusting the masked 
hypertension prevalence, higher treatment costs and increased use of ABPM in individuals 
with apparently normal screening BPs (<140/90 mm Hg). The findings suggest that a 
strategy of targeted use of ABPM in individuals with high or high-normal screening BP is 
likely to be cost-effective at a willingness to pay of £20,000 per QALY gained, and results in 
increased quality of life and lower mortality rate for individuals with hypertension. 
Strengths and weaknesses 
The major strength of this work is that it represents a direct update of the cost-effectiveness 
model that informed the NICE hypertension guidance and which currently underpins the use 
of ABPM in routine clinical practice in the UK.2 This means that this new strategy of targeted 
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use of ABPM using the PROOF-BP algorithm can be directly compared to the current UK 
reference standard approach for diagnosis of hypertension. A large number of sensitivity 
analyses were considered to test the robustness of assumptions in the model and 
consistently supported the base-case findings.  
The original analysis included a detailed discussion including potential limitations with the 
original model and these are not repeated here.4 Additional points are discussed below.  
One limitation of the model as used here, is that it assumed that individuals derived the 
same benefit from treatment of masked hypertension as applies to those with sustained 
hypertension. Although this has been suggested in a number of observational studies,15,22 
no randomised trial of treatment versus no treatment in individuals with masked 
hypertension has yet been reported. One previous study did examine the efficacy of 
treatment based on ABPM rather than clinic readings and reported similar levels of BP 
control at follow-up but less treatment in the intervention arm.23 However, this study did 
not include individuals with masked hypertension. A trial of treatment of masked 
hypertension is currently underway in the US,24 however this plans to enrol individuals with 
existing hypertension who are apparently controlled according to clinic BP, so the findings 
will not be directly relevant in the diagnostic scenario examined here. Until a randomised 
clinical trial of treatment in drug naïve individuals with masked hypertension is conducted, 
the true benefits of treatment will remain unknown. However, since the relationship 
between BP and vascular outcomes appears log-linear and predictable in epidemiological 
studies,25 it is reasonable to assume that treatment of masked (but true) hypertension 
carries similar benefit.  
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The present study used a prevalence of masked hypertension from the International 
Database on Ambulatory BP in relation to Cardiovascular Outcomes (IDACO).26 In fact, due 
to the difficulty recognising masked hypertension in routine clinical practice, the true 
prevalence has been shown to vary, with estimates ranging from 8·5 to 16·6%.22,27 We 
examined the impact of varying prevalence in a sensitivity analysis and the PROOF-BP 
algorithm remained cost-effective across the range assessed. 
As with the previous model that informed the latest NICE hypertension guidance,4 and in 
keeping with the results of the recent HOPE-3 trial ,28 the present analysis assumed that 
there was no benefit from treatment in individuals who were truly normotensive. This 
assumption has been challenged by the meta-analysis by Law and colleagues25 and more 
recently the SPRINT trial29 which support the prescription of treatment to those with BP 
levels of ≥130/80 mm Hg. However, SPRINT was a trial of individuals at high risk and less 
than 10% were treatment naïve at baseline, limiting the applicability of those results to a 
modelled population of undiagnosed individuals undergoing screening for hypertension. 
Sensitivity analyses undertaken in the present study also revealed assuming equal risk 
reduction in normotensive patients, or those undergoing intensive blood pressure lowering 
regimes would actually reduce the ICER in favour of the PROOF-BP algorithm. 
While the PROOF-BP algorithm was cost-effective when the model entry was widened to 
individuals with a screening BP ≥120/70 mm Hg, the increased primary care workload 
burden from the additional ABPM investigations (Table S9 in the online-only Data 
Supplement) would likely make implementation infeasible (between 1·57 to 6·85 times 
more ABPM investigations by cohort than current practice). 
Findings in the context of existing literature 
14 
 
PROOF-BP Economic Evaluation 
There are a number of economic analyses examining the cost-effectiveness and cost benefit 
of different BP monitoring strategies in the diagnosis of hypertension. Previous studies from 
Australia, USA and Europe have compared ABPM with CBPM30-33 and further studies from 
Japan and the USA have compared HBPM with CBPM.34,35 The original cost-effectiveness 
model developed for NICE,2 which formed the basis for the present analyses, was the first to 
compare all three strategies. All previous analyses found diagnosis with out-of-office 
monitoring to be cost-effective, but only examined individuals with a high screening BP and 
examined strategies which targeted the use of ABPM or HBPM monitoring at those most 
likely to benefit. A recent analysis compared the cost-effectiveness of central BP monitoring 
with CBPM and found the former to be cost-effective, although they did not compare it with 
ABPM or HBPM.36 
The present analysis examined the cost-effectiveness of a new strategy designed to target 
the use of ABPM at those displaying a potential white coat or masked effect, something 
which has not been attempted before. Utilisation of the PROOF-BP algorithm was found to 
be cost-effective at all ages and in males and females, primarily due to treatment of masked 
hypertension. Some variation by gender was observed, which may be attributable to the 
varying Framingham risk profile14 between genders: females had a lower cardiovascular risk 
which limited the benefits of antihypertensive treatment.  
Scenarios where the PROOF-BP risk algorithm was not the most cost-effective option 
centred on adjustments in treatment disutility. All strategies that increased the proportion 
of individuals receiving treatment (in the case of PROOF-BP, treating masked hypertension) 
were disadvantaged when quality of life decrement penalties due to treatment side-effects 
were assumed. The level of treatment disutility associated with antihypertension 
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medication is a matter of debate and may vary with age. The non-inclusion of disutility in 
the present analysis base-case was consistent with previous modelling which argued that 
where side effects exist, individuals can switch to alternative drugs.4  
Implications for clinical practice 
The present analyses suggest that using the PROOF-BP algorithm was likely to result in 
slightly higher healthcare costs (due to increased utilisation of treatment in masked 
hypertensives) but improved quality of life in individuals screened for hypertension. The 
PROOF-BP algorithm is not currently utilised in routine clinical practice but implementation 
would be possible with relative ease: automated BP monitors which take up to three 
consecutive readings (required for the decision tool) are now cheap and routinely available. 
The prediction algorithm is already available as an online calculator 
(https://sentry.phc.ox.ac.uk/proof-bp) and could easily be incorporated into general 
practice computer systems or built into smartphones linked to BP monitors. This strategy 
has the potential for individuals with apparently normal clinic BP to end up on treatment (if 
they have masked hypertension), which represents a notable shift from the current practice 
model and therefore would require some ‘buy in’ from both patients and practitioners. 
Presenting the evidence and treatment options clearly, perhaps through formal patient and 
practitioner education may be required, in much the same way that it accompanied the 
adoption of ABPM into routine Primary Care. 
Perspectives 
Current guidelines recommend use of out-of-office measurements to confirm hypertension 
diagnosis for individuals with raised clinic BP readings. The PROOF-BP algorithm considers 
both normal and raised clinic BP individuals with less reliance on out-of-office 
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measurements to confirm hypertension diagnosis. Targeted use of ABPM (PROOF-BP 
algorithm) in the diagnosis of hypertension appears to be cost-effective compared to the 
conventional BP diagnostic options in Primary Care and would lead to reduced death and 
disability. Limitations of the model include the lack of data on the assumed efficacy of 
antihypertensive treatment for masked hypertension, which requires further investigation. 
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Novelty and Significance 
What Is New? 
• This study considered the merits (cost-effectiveness) of using the PROOF-BP 
algorithm to triage for Ambulatory Blood Pressure Monitoring (ABPM) in the 
diagnosis of hypertension  
• This is the first economic evaluation of different methods of diagnosing hypertension 
which includes the consideration of individuals with potential masked hypertension  
What Is Relevant? 
• PROOF-BP algorithm considered a broader screening population in terms of clinic BP 
for diagnosis but necessitated less ABPM investigations in most age cohorts 
compared with current guidelines. 
Summary 
• Economic modelling suggest such an approach would be cost-effective compared 
with conventional BP diagnostic options in Primary Care 
Figure Legends 
Figure 1. Diagnostic strategies examined 
Figure 2. Markov state transition diagram 
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Tables 
Table 1. Clinical data inputs for the model 
Clinical data for the model Data Source 
Prevalence of true 
hypertension in population 
suspected of having 
hypertension* (Clinic BP 
≥140/90 mm Hg) 
17-64% (age and sex 
dependent) 
Estimated with meta-analysis 
by Hodgkinson and colleagues13 
and HSE 201312 
Prevalence of masked 
hypertension in screening 
population (Clinic BP 
≥130/80 mm Hg) 
1-15% (age and sex 
dependent) 
Estimated from Conen and 
colleagues26 and HSE 201312 
Diagnosis inputs 
Clinic BP ≥140/90 mm Hg 
Sensitivity  
CBPM 85·6% (95% CI 81·0-
89·2); 
HBPM 85·7% (95% CI 78·0-
91·0); 
ABPM 100·0%; 
PROOF-BP 100·0% 
Meta-analysis sensitivity 
analysis by Hodgkinson and 
colleagues13 (excluding 
populations with low mean BP); 
ABPM was assumed to be 
reference standard with 100% 
sensitivity and specificity. 
PROOF-BP data taken from 
Sheppard and colleagues11 
Clinic BP ≥140/90 mm Hg 
Specificity  
CBPM 45·9% (95% CI 33·0-
59·3); 
HBPM 62·4% (95% CI 48·0-
75·0) ABPM 100·0%; 
PROOF-BP 65·5% 
As above 
Clinic BP between 130/80 
mm Hg & 140/90 mm Hg 
Sensitivity  
CBPM, HBPM, ABPM 0%  
PROOF-BP 97·3% 
Assumed not hypertensive in 
conventional strategies. 
PROOF-BP data taken from 
Sheppard and colleagues11  
Clinic BP between 130/80 
mm Hg & 140/90 mm Hg 
Specificity 
CBPM, HBPM, ABPM 100% 
PROOF-BP 96·2% 
As above 
Sensitivity Analysis: Clinic BP 
between 120/80 mm Hg & 
140/90 mm Hg Sensitivity  
CBPM, HBPM, ABPM 0%  
PROOF-BP 89·5% 
As above 
Sensitivity Analysis: Clinic BP 
between 120/80 mm Hg & 
140/90 mm Hg Specificity  
CBPM, HBPM, ABPM 100% 
PROOF-BP 97·6% 
As above 
Time until diagnosis 
complete 
CBPM 3 months; HBPM 1 
month; ABPM 1 month; 
PROOF-BP 1 month 
Assumption based on guideline 
recommendations 
Diagnostic device failure rate ABPM 5% Assumption 
Mortality and risk of cardiovascular disease 
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Probability of non-
cardiovascular death 
Age and sex dependent England and Wales 2011-2013 
lifetables without circulatory 
death37,38 
Probability of coronary heart 
disease event if truly 
normotensive within 10 
years 
0·8-14·9% (age and sex 
dependent) 
Calculated with Framingham 
coronary heart disease and 
stroke risk equations14 and risk 
factor profile based on HSE 
201312 
Probability of coronary heart 
disease event if truly 
hypertensive within 10 years 
1·7-22·2% (age and sex 
dependent) 
As above 
Probability of stroke event if 
truly normotensive within 10 
years  
0·3-4·8% (age and sex 
dependent) 
As above 
Probability of stroke event if 
truly hypertensive within 10 
years  
0·8-14·8% (age and sex 
dependent) 
As above 
Coronary heart disease event 
distribution (age and sex 
dependent) 
MI 14·3-37·8%; unstable 
angina 10·4-20·9%; stable 
angina 37·7-62·9%; 
coronary heart disease 
death 6·6-17·8% 
Ward and colleagues39 
Stroke event distribution 
(age and sex dependent) 
Stroke 51·7-70·1%; TIA 
13·4-36·1%; stroke death 
12·2-16·5% 
Ward and colleagues39 
Relative Risk of coronary 
heart events on treatment –
true positives  
0·639-0·721 (age and sex 
dependent) 
Calculated with meta-analysis 
by Law and colleagues25 and 
HSE distribution of people on 1-
3 drugs12 
Relative Risk of coronary 
heart events on treatment –
false positives 
1 Assumption that people 
without raised BP get no 
treatment benefit  
Relative Risk of stroke events 
on treatment—true positives 
0·533-0·721  
(age and sex dependent) 
Calculated with meta-analysis 
by Law and colleagues25 and 
HSE distribution of people on 1-
3 drugs12 
Relative Risk of stroke events 
on treatment—false 
positives 
1 Assumption that people 
without raised BP get no 
treatment benefit 
Standardized Mortality Rate 
(SMR) after myocardial 
infarction  
2·68 (95% CI 2·48-2·91) Brønnum-Hansen and 
colleagues40 
SMR after unstable angina  2·19 (95% CI 2·05-2·33) NICE guidelines41  
SMR after stable angina  1·95 (95% CI 1·65-2·31) Rosengren and colleagues42 
SMR after stroke  2·72 (95% CI 2·59-2·85) Brønnum-Hansen and 
colleagues40 
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SMR after transient 
ischaemic attack  
1·40 (95% CI 1·1-1·8) Oxfordshire Community Stroke 
Project43 
BP over time and ongoing 
monitoring 
  
Probability of raised BP (true 
positive and false positive) 
13-34% (age and sex 
dependent) 
Calculated based on HSE 201312 
Proportion of masked 
hypertension that progress 
to sustained hypertension by 
3 years  
26·3% Trudel and colleagues44 
Proportion of masked 
hypertension that progress 
to sustained hypertension by 
5 years 
34·9% Trudel and colleagues44 
Check-up frequency if 
diagnosed not hypertensive 
Every 5 years Assumption based on present 
UK practice 
Diagnosis method following 
check-up 
Same as initial diagnosis 
method 
 
CBPM, Clinic Blood Pressure Monitoring; HBPM, Home Blood Pressure monitoring; ABPM, 
Ambulatory Blood Pressure Monitoring; PROOF-BP, Predicting out-of-office blood pressure; 
TIA, Transient Ischaemic Attack; MI, Myocardial infarction; NICE, National Institute for 
Health and Care Excellence; HSE, Health Survey for England; 
*Left ventricular hypertrophy risk input assumed to be 0% 
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Table 2. Quality of life and cost data inputs for the model  
Quality of life weights  Data Source 
No cardiovascular event 0·737-0·905  
(age and sex dependent) 
General population utilities 
from analysis of EQ-5D (UK 
tariff) from HSE 201216 
Quality of life multipliers   
Stroke 0·629 Ward and colleagues.39 Applied 
multiplicatively to general 
population age-dependent and 
sex-dependent utilities 
Myocardial infarction 0·760 As above 
Unstable Angina 0·770 As above 
Stable Angina 0·808 As above 
Transient Ischaemic Attack 1 As above 
On hypertension treatment 1 Assumption that no quality of 
life loss to treatment in base-
case 
Costs   
Cost of diagnosis CBPM £46·37 Calculated based on resource-
use assumptions from Lovibond 
and colleagues4 and UK unit 
costs below 
Cost of diagnosis HBPM £47·59 As above 
Cost of diagnosis ABPM £63·61 As above 
Cost of diagnosis PROOF-BP £0-£63·61 Cost of diagnosis of ABPM if 
decision rule suggests 
confirmatory investigation, 
zero otherwise (zero assumed 
cost of using algorithm) 
Practice nurse consultation £11·37 PSSRU 2014 unit costs17 
GP consultation £35·00 PSSRU 2014 unit costs17 
HBPM device £46·00 Median price of approved 
HBPM devices from NHS supply 
chain catalogue; only monitors 
also on the British 
Hypertension Society list of 
validated devices suitable for 
home use were used 
ABPM device £1,105 Median price from NHS supply 
chain catalogue 
HBPM calibration/services per 
year 
£10·00 Data on File at Greenridge 
Surgery, South Birmingham 
primary-care trust (Richard J 
McManus, unpublished,2011) 
ABPM 
calibration/service/parts per 
£413 Mean of two estimates 
(£460·00 and £300·00) updated 
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year to 2013-1417 
Battery (1·5 volt size AA/LR6 
high power alkaline) 
£0·29 NHS supply chain catalogue 
Adult cuff £17·41 Median price in NHS supply 
chain catalogue 
Nurse practitioner 
consultation 
£22·00 PSSRU 2014 unit costs17 
Annual hypertension 
treatment cost 
£58·01-64·90 Calculated based on 
recommended treatment and 
UK unit costs2,12,17 
Initial stroke costs (3 months) £8,390 Luengo-Fernandez and 
colleagues45 
Post-stroke costs (3 months) £336 Luengo-Fernandez and 
colleagues45 
Initial cost of TIA (3 months) £1,045 Diagnostic tests and 
procedures: Ward and 
colleagues inflated to 2013-
14;17 drug costs: relevant NICE 
guidance46,47 and British 
National Formulary 6948 
Costs after TIA (3 months) £19·56 Relevant NICE guidance46,47 and 
British National Formulary 6948 
Initial myocardial infarction 
costs (3 months) 
£5,183 Palmer and colleagues inflated 
to 2013-1417 
Costs after myocardial 
infarction (3 months) 
£152 Taylor and colleagues49 
Initial unstable angina costs  
(3 months) 
£3,110 Assumed to be 60% of initial 
costs of myocardial infarction 
Costs after unstable angina  
(3 months) 
£91 Assumed to be 60% of costs 
after myocardial infarction 
Initial stable angina cost  
(3 months) 
£397 An outpatient cardiology 
assessment (service code 320) 
plus non-invasive imaging 
SPECT scan (service code 
RA37Z)50  
Costs after stable angina  
(3 months) 
£8 Relevant NICE guidelines51 and 
British National Formulary 6948 
Check-up £35 PSSRU 2014 unit costs17 
CBPM, Clinic Blood Pressure Monitoring; HBPM, Home Blood Pressure monitoring; ABPM, 
Ambulatory Blood Pressure Monitoring; GP, General Practitioner; PROOF-BP, Predicting out-
of-office blood pressure; NICE, National Institute of Health and Care Excellence; PSSRU, 
Personal Social Services Research Unit; TIA, Transient Ischaemic Attack 
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Table 3. Base-case model results when entry is restricted to clinic BP ≥130/80 mm Hg  
Strategy QALYs 
(95% CI) 
Costs  
(95% CI) 
ICER Most CE 
strategy 
probability 
Strategy QALYs 
(95% CI) 
Costs  
(95% CI) 
ICER Most CE 
strategy 
probability 
40 years, 
Male 
    40 years, 
Female 
    
ABPM 18·116 
(17·867 to 
18·34) 
£3275 (£3181 
to £3440) 
 
0% 
ABPM 18·006 
(17·807 to 
18·209) 
£1989 
(£1911 to 
£2132) 
 0% 
PROOF-
BP 
18·153 
(17·906 to 
18·377) 
£3389 (£3301 
to £3540) 
£3081 
100% 
HBPM 18·007 
(17·808 to 
18·209) 
£2148 
(£2064 to 
£2257) 
Dominated 0% 
HBPM 18·115 
(17·865 to 
18·340) 
£3397 (£3310 
to £3520) 
Dominated 
0% 
PROOF-BP 18·020 
(17·823 to 
18·222) 
£2153 
(£2067 to 
£2286) 
£11363 100% 
CBPM 18·115 
(17·864 to 
18·339) 
£3427 (£3345 
to £3537) 
Dominated 
0% 
CBPM 18·007 
(17·808 to 
18·210) 
£2188 
(£2112 to 
£2288) 
Dominated 0% 
50 years, 
Male 
    50 years, 
Female 
    
ABPM 15·604 
(15·365 to 
15·858) 
£3405 (£3269 
to £3597) 
 0% ABPM 15·426 
(15·207 to 
15·627) 
£2269 
(£2154 to 
£2453) 
 0% 
PROOF-
BP 
15·633 
(15·399 to 
15·884) 
£3468 (£3344 
to £3640) 
£2094 100% PROOF-BP 15·442 
(15·223 to 
15·643) 
£2372 
(£2262 to 
£2544) 
£6232 100% 
HBPM 15·599 
(15·360 to 
15·855) 
£3504 (£3390 
to £3649) 
Dominated 0% HBPM 15·425 
(15·207 to 
15·627) 
£2385 
(£2277 to 
£2534) 
Dominated 0% 
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CBPM 15·598 
(15·359 to 
15·854) 
£3530 (£3424 
to £3668) 
Dominated 0% CBPM 15·426 
(15·205 to 
15·628) 
£2416 
(£2314 to 
£2556) 
Dominated 0% 
60 years, 
Male 
    60 years, 
Female 
    
ABPM 12·842 
(12·624 to 
13·060) 
£3193 (£3018 
to £3428) 
 0% ABPM 12·528 
(12·315 to 
12·735) 
£2346 
(£2161 to 
£2634) 
 0% 
PROOF-
BP 
12·862 
(12·646 to 
13·079) 
£3226 (£3069 
to £3449) 
£1680 100% PROOF-BP 12·537 
(12·325 to 
12·743) 
£2383 
(£2217 to 
£2651) 
£3865 100% 
HBPM 12·835 
(12·618 to 
13·054) 
£3280 (£3120 
to £3483) 
Dominated 0% HBPM 12·525 
(12·314 to 
12·729) 
£2459 
(£2289 to 
£2696) 
Dominated 0% 
CBPM 12·833 
(12·617 to 
13·053) 
£3305 (£3161 
to £3500) 
Dominated 0% CBPM 12·525 
(12·314 to 
12·730) 
£2490 
(£2344 to 
£2711) 
Dominated 0% 
70 years, 
Male 
    70 years, 
Female 
    
ABPM 9·821 
(9·569 to 
10·026) 
£2686 (£2440 
to £2989) 
 0% ABPM 9·357 
(9·120 to 
9·590) 
£2021 
(£1797 to 
£2314) 
 0% 
PROOF-
BP 
9·830 
(9·577 to 
10·038) 
£2695 (£2472 
to £2988) 
£955 100% PROOF-BP 9·364 
(9·128 to 
9·596) 
£2040 
(£1832 to 
£2314) 
£2789 100% 
HBPM 9·812 
(9·558 to 
10·019) 
£2765 (£2552 
to £3043) 
Dominated 0% HBPM 9·351 
(9·115 to 
9·584) 
£2088 
(£1892 to 
£2344) 
Dominated 0% 
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CBPM 9·810 
(9·556 to 
10·017) 
£2790 (£2588 
to £3055) 
Dominated 0% CBPM 9·350 
(9·112 to 
9·585) 
£2110 
(£1914 to 
£2356) 
Dominated 0% 
75 years, 
Male 
    75 years, 
Female 
    
PROOF-
BP 
8·235 
(7·987 to 
8·490) 
£2430 (£2175 
to £2755) 
Dominant 100% PROOF-BP 7·689 
(7·412 to 
7·975) 
£1818 
(£1583 to 
£2164) 
Dominant 100% 
ABPM 8·230 
(7·981 to 
8·484) 
£2434 (£2166 
to £2773) 
Dominated 0% ABPM 7·687 
(7·411 to 
7·973) 
£1822 
(£1584 to 
£2183) 
Dominated 0% 
HBPM 8·222 
(7·972 to 
8·476) 
£2495 (£2250 
to £2815) 
Dominated 0% HBPM 7·682 
(7·406 to 
7·970) 
£1884 
(£1664 to 
£2215) 
Dominated 0% 
CBPM 8·219 
(7·969 to 
8·470) 
£2516 (£2273 
to £2829) 
Dominated 0% CBPM 7·681 
(7·403 to 
7·967) 
£1906 
(£1687 to 
£2228) 
Dominated 0% 
Results are per patient & strategies are ordered by ascending costs; CBPM, Clinic Blood Pressure Monitoring; HBPM, Home Blood Pressure 
monitoring; ABPM, Ambulatory Blood Pressure Monitoring; PROOF-BP, Predicting out-of-office blood pressure; QALYs, quality-adjusted life 
years; ICER= Incremental Cost-Effectiveness Ratio 
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Table 4. Sensitivity Analysis Scenarios 
Strategy QALYs Costs ICER Strategy QALYs Costs ICER 
Base-case Risk reduction based on half doses for masked hypertensives 
ABPM 12·842 £3193  ABPM 12·840 £3,199  
PROOF-BP 12·862 £3226 £1680 PROOF-BP 12·857 £3,240 £2504 
HBPM 12·835 £3280 Dominated HBPM 12·833 £3,286 Dominated 
CBPM 12·833 £3305 Dominated CBPM 12·831 £3,310 Dominated 
1% utility decrement on treatment Higher prevalence of masked hypertension (125%) 
ABPM 12·786 £3,193  ABPM 12·837 £3,213  
PROOF-BP 12·790 £3,226 £7620 PROOF-BP 12·861 £3,240 £1193 
HBPM 12·764 £3,280 Dominated HBPM 12·830 £3,300 Dominated 
CBPM 12·757 £3,305 Dominated CBPM 12·828 £3,325 Dominated 
2% utility decrement on treatment Lower prevalence of masked hypertension (75%) 
ABPM 12·730 £3,193 Dominant ABPM 12·847 £3,174  
PROOF-BP 12·719 £3,226 Dominated PROOF-BP 12·863 £3,212 £2375 
HBPM 12·693 £3,280 Dominated HBPM 12·839 £3,261 Dominated 
CBPM 12·682 £3,305 Dominated CBPM 12·838 £3,286 Dominated 
Higher hypertension treatment costs  Antihypertensive treatment benefits assumed for all people 
ABPM 12·842 £3,277  ABPM 12·846 £3,185  
PROOF-BP 12·862 £3,326 £2470 PROOF-BP 12·878 £3,185 £20 
HBPM 12·835 £3,380 Dominated HBPM 12·862 £3,214 Dominated 
CBPM 12·833 £3,409 Dominated CBPM 12·867 £3,223 Dominated 
Risk reduction based on half doses Antihypertensive intensive treatment assumed 
ABPM 12·811 £3,276  ABPM 12·903 £3,093  
PROOF-BP 12·827 £3,318 £2572 PROOF-BP 12·930 £3,115 £852 
HBPM 12·805 £3,361 Dominated HBPM 12·893 £3,183 Dominated 
CBPM 12·803 £3,385 Dominated CBPM 12·891 £3,208 Dominated 
ABPM strategy considers individuals with a screening clinic BP of 
130/80 mm Hg ABPM failure rate increased from 5% to 17% 
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ABPM 12·860 £3,219  ABPM 12·841 £3,224  
PROOF-BP 12·862 £3,226 £5153 PROOF-BP 12·861 £3,250 £1287 
HBPM 12·835 £3,280 Dominated HBPM 12·835 £3,280 Dominated 
CBPM 12·833 £3,305 Dominated CBPM 12·833 £3,305 Dominated 
BP check-up frequency is reduced from every 5 years to every 3 years     
ABPM 12.847 £3,253      
PROOF-BP 12.865 £3,294 £2,315     
HBPM 12.842 £3,320 Dominated     
CBPM 12.840 £3,333 Dominated     
Results are per patient & strategies are ordered by ascending costs; CBPM, Clinic Blood Pressure Monitoring; HBPM, Home Blood Pressure 
monitoring; ABPM, Ambulatory Blood Pressure Monitoring; PROOF-BP, Predicting out-of-office blood pressure; QALYs, quality-adjusted life 
years; ICER= Incremental Cost-Effectiveness Ratio 
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Figures 
 
Figure 1. Diagnostic strategies examined 
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Figure 2. Markov state transition diagram 
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